MedTrace Logo

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

NCT05827068 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 698

Last updated 2025-02-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to measure the safety and the immune response to 3 next-generation influenza vaccine candidates (mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1) compared with influenza vaccine candidate mRNA-1010 controls in healthy adult participants.

Conditions

Interventions

BIOLOGICAL

mRNA-1011.1

Sterile liquid for injection

BIOLOGICAL

mRNA-1011.2

Sterile liquid for injection

BIOLOGICAL

mRNA-1012.1

Sterile liquid for injection

BIOLOGICAL

mRNA-1010

Sterile liquid for injection

BIOLOGICAL

mRNA-1010.2

Sterile liquid for injection

BIOLOGICAL

mRNA-1010.3

Sterile liquid for injection

Sponsors & Collaborators

  • ModernaTX, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-27
Primary Completion
2023-11-20
Completion
2023-11-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05827068 on ClinicalTrials.gov